– UK, London – BenevolentAI (AMS: BAI), a leading, clinical-stage AI-enabled drug discovery and development company, today announced the appointment of Marcello Damiani to its Board as an Independent Non-Executive Director, to be confirmed by the AGM on 4 May 2023.
“We are pleased to welcome Marcello to our Board as a Non-Executive Director. Drawing from his senior executive leadership experience at global organizations such as Moderna and bioMérieux, Marcello offers a unique perspective and understanding of innovation in the technology and biotech sectors. His experience will further strengthen the existing diversity and knowledge of our Board as BenevolentAI continues to execute its ambitious growth strategy.” said Board Chairman, Dr. François Nader.
Joanna Shields, the CEO, added: “BenevolentAI is, at its core, a technology development company with a mission to understand complex disease biology and enable scientists to make novel discoveries. Marcello’s expertise in driving innovation in biopharma will be an invaluable addition to our Board as we continue to scale the impact of our platform and AI tools.”
About Marcello Damiani
Marcello Damiani has over 25 years of experience in senior executive positions in both private and publicly listed companies in the aerospace, high-tech, and biotech industries. He is the former Chief Digital and Operational Excellence Officer of Moderna Inc. (Nasdaq: MRNA), where he built the technology, processes, and digitization landscape required to advance a new class of medicines based on mRNA science. Before joining Moderna in 2015, he served as Sr. Vice President & group CIO at bioMérieux from 2010 to 2015, having joined in 2009 as Executive Director, of IT Global Infrastructure services.
Marcello Damiani, said: “Technologies such as artificial intelligence offer huge promise to unlock complex biology and uncover new medicines for a broad range of debilitating diseases. I am delighted to work alongside BenevolentAI’s Board of Directors and leadership team to deliver on this promise and, in so doing, deliver a new generation of transformative medicines to patients.”
Marcello holds an MBA from TRIUM, an MSc in Information Systems Architecture from the University of Toulouse, France, and a BSc in Computer Science from the University of Toulouse, France. He also serves on the Board of Cellarity, a biotech company based in Cambridge, MA.
About BenevolentAI
BenevolentAI is a leading, clinical-stage AI-enabled drug discovery and development company listed on the Euronext Amsterdam stock exchange. Through the combined capabilities of this AI platform, its scientific expertise, and wet-lab facilities, BenevolentAI is well-positioned to deliver novel drug candidates with a higher probability of clinical success than those developed using traditional methods. The Benevolent
Platform powers the Company’s in-house drug pipeline and supports successful collaborations with AstraZeneca, as well as leading research and charitable institutions. BenevolentAI is headquartered in London, with a research facility in Cambridge (UK) and a further office in New York.
Source: https://www.benevolent.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.